Unique in its focus on adolescents, the trial shows the cardiac myosin inhibitor safely reduces LVOT in the pediatric ...
MedPage Today on MSN
Mavacamten poised to expand to pediatric obstructive hypertrophic cardiomyopathy
The cardiac myosin inhibitor gets a big win in the SCOUT-HCM trial ...
During migration in tissue in vivo or in culture in a three-dimensional (3D) extracellular matrix (ECM), endothelial cells, fibroblasts and tumour cells exhibit a characteristic complex shape that ...
Our interest in this topic stems from our work with human muscle myosins II and mutations in them that cause cardiac and skeletal muscle disease. We recently developed a mammalian overexpression ...
JUPITER, Fla., July 7, 2025 /PRNewswire/ -- Myosin Therapeutics, a clinical-stage biotechnology company advancing first-in-class therapies targeting molecular motor proteins, announced the publication ...
Myosin Therapeutics today announced that it has been awarded $2 million in funding from the Florida Department of Health ...
Each year, about 14,000 people in the United States are diagnosed with glioblastoma, one of the deadliest primary brain tumors. With standard treatments of surgery, radiation, and chemotherapy ...
The novel cardiac myosin inhibitor aficamten improved peak oxygen uptake in symptomatic obstructive hypertrophic cardiomyopathy (HCM), the pivotal SEQUOIA-HCM trial showed. At 24 weeks, the mean ...
The team showed with microsecond resolution that the head of myosin first binds weakly to actin. That bond strengthens, however, as myosin moves along the actin filament and finds the position for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results